StockWatch
·
Biotechnology: Pharmaceutical Preparations
USFDANov 20, 2026, 08:02 AM

Belite Bio: FDA Extends Tinlarebant Review to May 2027

AI Summary

Belite Bio, Inc. announced that the U.S. FDA has extended the review period for its New Drug Application (NDA) for tinlarebant, a treatment for Stargardt disease type 1 (STGD1). The Prescription Drug User Fee Act (PDUFA) action date has been moved to May 12, 2027. The FDA also indicated that proposed labeling and postmarketing requirement requests, if any, would be communicated by April 12, 2027, provided no major deficiencies are found. The company remains confident in the clinical evidence supporting tinlarebant.

Key Highlights

  • FDA extends review period for tinlarebant NDA for Stargardt disease type 1 (STGD1).
  • New PDUFA action date set for May 12, 2027, a three-month extension.
  • FDA to communicate proposed labeling/postmarketing requests by April 12, 2027, if no major deficiencies.
  • Belite Bio confident in clinical evidence for tinlarebant.
  • Tinlarebant is an oral therapy designed to reduce bisretinoid accumulation in the eye.